ERK (MAPK) does not phosphorylate tau under physiological conditions invivo or invitro

Neurobiology of Aging

Volumn 36, Issue 2, 2015, Pages 901-902

  Noël, Anastasia ^a,b   Poitras, Isabelle ^a,b   Julien, Jacinthe ^b   Petry, Franck R ^a,b   Morin, Françoise ^b   Charron, Jean ^c   Planel, Emmanuel ^a,b  

^a UNIVERSITÉ LAVAL   (Canada)

^b LAVAL UNIVERSITY   (Canada)

^c Université Laval   (Canada)

Author keywords

ERK1 2; Hyperthermia; Hypothermia; MAPK; MEK1 2; PD0325901; PD184161; PD98059; SH SY5Y; Tau phosphorylation

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; TAU PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE KINASE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL LINE; CONTROLLED STUDY; CORRELATIONAL STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PHYSIOLOGICAL PROCESS; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SH SY5Y CELL LINE; ALZHEIMER DISEASE; ANIMAL; C57BL MOUSE; CELL CULTURE; HUMAN; HYPERTHERMIC THERAPY; INDUCED HYPOTHERMIA; KNOCKOUT MOUSE; METABOLISM; MOLECULARLY TARGETED THERAPY; PHOSPHORYLATION; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ALZHEIMER DISEASE; ANIMALS; CELLS, CULTURED; HUMANS; HYPERTHERMIA, INDUCED; HYPOTHERMIA, INDUCED; IN VITRO TECHNIQUES; MAP KINASE SIGNALING SYSTEM; MICE, INBRED C57BL; MICE, KNOCKOUT; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MOLECULAR TARGETED THERAPY; PHOSPHORYLATION; TAU PROTEINS;

EID: 84922894730     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2014.11.005     Document Type: Article

References (16)

1. Anderton B.H., Brion J.P., Couck A.M., Davis D.R., Gallo J.M., Hanger D.P., Ladhani K., Latimer D.A., Lewis C., Lovestone S., Marquardt B., Miller C.C.J., Mulot S.F.C., Reynolds C.H., Rupniak T., Smith C.J., Stabel S., Woodgett J.R. Modulation of PHF-like tau phosphorylation in cultured neurones and transfected cells. Neurobiol. Aging 1995, 16:389-397. discussion 98-402.
2. Bain J., Plater L., Elliott M., Shpiro N., Hastie C.J., McLauchlan H., Klevernic I., Arthur J.S., Alessi D.R., Cohen P. The selectivity of protein kinase inhibitors: a further update. Biochem. J. 2007, 408:297-315.
3. Belanger L.F., Roy S., Tremblay M., Brott B., Steff A.M., Mourad W., Hugo P., Erikson R., Charron J. Mek2 is dispensable for mouse growth and development. Mol. Cell. Biol. 2003, 23:4778-4787.
4. Bissonauth V., Roy S., Gravel M., Guillemette S., Charron J. Requirement for Map2k1 (Mek1) in extra-embryonic ectoderm during placentogenesis. Development 2006, 133:3429-3440.
5. Bretteville A., Marcouiller F., Julien C., El Khoury N.B., Petry F.R., Poitras I., Mouginot D., Levesque G., Hebert S.S., Planel E. Hypothermia-induced hyperphosphorylation: a new model to study tau kinase inhibitors. Scientific Rep. 2012, 2:480.
6. Drewes G., Lichtenberg-Kraag B., Doring F., Mandelkow E.M., Biernat J., Goris J., Doree M., Mandelkow E. Mitogen activated protein (MAP) kinase transforms tau protein into an Alzheimer-like state. EMBO J. 1992, 11:2131-2138.
7. Ekinci F.J., Shea T.B. Hyperactivation of mitogen-activated protein kinase increases phospho-tau immunoreactivity within human neuroblastoma: additive and synergistic influence of alteration of additional kinase activities. Cell Mol. Neurobiol. 1999, 19:249-260.
8. Ferrer I., Blanco R., Carmona M., Ribera R., Goutan E., Puig B., Rey M.J., Cardozo A., Vinals F., Ribalta T. Phosphorylated map kinase (ERK1, ERK2) expression is associated with early tau deposition in neurones and glial cells, but not with increased nuclear DNA vulnerability and cell death, in Alzheimer disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration. Brain Pathol. 2001, 11:144-158.
9. Houser C.R., Huang C.S., Peng Z. Dynamic seizure-related changes in extracellular signal-regulated kinase activation in a mouse model of temporal lobe epilepsy. Neuroscience 2008, 156:222-237.
10. Jiang X., Knox R., Pathipati P., Ferriero D. Developmental localization of NMDA receptors, Src and MAP kinases in mouse brain. Neurosci. Lett. 2011, 503:215-219.
11. Lovestone S., Reynolds C.H., Latimer D., Davis D.R., Anderton B.H., Gallo J.M., Hanger D., Mulot S., Marquardt B., Stabel S., Woodget J.R., Miller C.C.J. Alzheimer's disease-like phosphorylation of the microtubule-associated protein tau by glycogen synthase kinase-3 in transfected mammalian cells. Curr. Biol. 1994, 4:1077-1086.
12. Martin L., Latypova X., Wilson C.M., Magnaudeix A., Perrin M.L., Yardin C., Terro F. Tau protein kinases: involvement in Alzheimer's disease. Ageing Res. Rev. 2013, 12:289-309.
13. Planel E., Richter K.E., Nolan C.E., Finley J.E., Liu L., Wen Y., Krishnamurthy P., Herman M., Wang L., Schachter J.B., Nelson R.B., Lau L.F., Duff K.E. Anesthesia leads to tau hyperphosphorylation through inhibition of phosphatase activity by hypothermia. J.Neurosci. 2007, 27:3090-3097.
14. Reynolds C.H., Betts J.C., Blackstock W.P., Nebreda A.R., Anderton B.H. Phosphorylation sites on tau identified by nanoelectrospray mass spectrometry: differences invitro between the mitogen-activated protein kinases ERK2, c-Jun N-terminal kinase and P38, and glycogen synthase kinase-3beta. J.Neurochem. 2000, 74:1587-1595.
15. Wauson E.M., Guerra M.L., Barylko B., Albanesi J.P., Cobb M.H. Off-target effects of MEK inhibitors. Biochemistry 2013, 52:5164-5166.
16. Yoshiyama Y., Lee V.M., Trojanowski J.Q. Therapeutic strategies for tau mediated neurodegeneration. J.Neurol. Neurosurg. Psychiatry 2013, 84:784-795.